WO1998004220A1 - Intravaginal rings with insertable drug-containing core - Google Patents
Intravaginal rings with insertable drug-containing core Download PDFInfo
- Publication number
- WO1998004220A1 WO1998004220A1 PCT/US1997/012777 US9712777W WO9804220A1 WO 1998004220 A1 WO1998004220 A1 WO 1998004220A1 US 9712777 W US9712777 W US 9712777W WO 9804220 A1 WO9804220 A1 WO 9804220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- core
- vaginal ring
- drug
- channel
- polymeric material
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 128
- 229940079593 drug Drugs 0.000 title claims abstract description 126
- 239000006213 vaginal ring Substances 0.000 claims abstract description 121
- 229940044953 vaginal ring Drugs 0.000 claims abstract description 92
- 239000000463 material Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000003433 contraceptive agent Substances 0.000 claims abstract description 12
- 229940124558 contraceptive agent Drugs 0.000 claims abstract description 10
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 36
- 229960002568 ethinylestradiol Drugs 0.000 claims description 35
- -1 methyldiacetoxysilyl end groups Chemical group 0.000 claims description 24
- 150000003431 steroids Chemical class 0.000 claims description 23
- 239000000565 sealant Substances 0.000 claims description 16
- 239000000853 adhesive Substances 0.000 claims description 13
- 230000001070 adhesive effect Effects 0.000 claims description 13
- 238000000465 moulding Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 9
- 229920001296 polysiloxane Polymers 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000583 progesterone congener Substances 0.000 claims description 8
- 229920002379 silicone rubber Polymers 0.000 claims description 6
- 230000001076 estrogenic effect Effects 0.000 claims description 5
- 230000001072 progestational effect Effects 0.000 claims description 5
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 229960001652 norethindrone acetate Drugs 0.000 claims description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 3
- 229930182833 estradiol Natural products 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 230000002254 contraceptive effect Effects 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 206010047700 Vomiting Diseases 0.000 abstract description 7
- 238000002657 hormone replacement therapy Methods 0.000 abstract description 7
- 230000003637 steroidlike Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- 229920001971 elastomer Polymers 0.000 description 15
- 239000000806 elastomer Substances 0.000 description 15
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 239000004205 dimethyl polysiloxane Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000004073 vulcanization Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001746 injection moulding Methods 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000013536 elastomeric material Substances 0.000 description 2
- CKFBRGLGTWAVLG-GOMYTPFNSA-N elcometrine Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 CKFBRGLGTWAVLG-GOMYTPFNSA-N 0.000 description 2
- 229950007611 elcometrine Drugs 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013464 silicone adhesive Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- WRXCBRHBHGNNQA-UHFFFAOYSA-N (2,4-dichlorobenzoyl) 2,4-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC(Cl)=CC=C1C(=O)OOC(=O)C1=CC=C(Cl)C=C1Cl WRXCBRHBHGNNQA-UHFFFAOYSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AYOHIQLKSOJJQH-UHFFFAOYSA-N dibutyltin Chemical compound CCCC[Sn]CCCC AYOHIQLKSOJJQH-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 229960005416 estradiol cypionate Drugs 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940106582 estrogenic substances Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 229940012028 ethynodiol diacetate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960001910 lynestrenol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 1
- 229960004190 nomegestrol acetate Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
- 229960002831 norgestrienone Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000011417 postcuring Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229940094938 stannous 2-ethylhexanoate Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU40431/97A AU4043197A (en) | 1996-07-31 | 1997-07-22 | Intravaginal rings with insertable drug-containing core |
BR9706802-0A BR9706802A (en) | 1996-07-31 | 1997-07-22 | Vaginal ring, vaginal ring body, set, and processes for administering a medicine to a woman and for preparing a vaginal ring. |
AT97938007T ATE290836T1 (en) | 1996-07-31 | 1997-07-22 | INTRAVAGINAL RINGS WITH INSERTABLE DRUG CONTAINING CORE |
JP50891598A JP3970936B2 (en) | 1996-07-31 | 1997-07-22 | Intravaginal ring with insertable drug-containing core |
EP97938007A EP0862396B1 (en) | 1996-07-31 | 1997-07-22 | Intravaginal rings with insertable drug-containing core |
DK97938007T DK0862396T3 (en) | 1996-07-31 | 1997-07-22 | Insertable intravaginal rings containing drug |
DE69732760T DE69732760T2 (en) | 1996-07-31 | 1997-07-22 | INTRAVAGINAL RINGS WITH INSERTABLE MEDICATION-CONTAINING CORE |
CA002232635A CA2232635C (en) | 1996-07-31 | 1997-07-22 | Intravaginal rings with insertable drug-containing core |
MXPA/A/1998/002349A MXPA98002349A (en) | 1996-07-31 | 1998-03-25 | Intravaginal rings with insertable drug-containing core |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2379296P | 1996-07-31 | 1996-07-31 | |
US60/023,792 | 1996-07-31 | ||
US08/850,327 | 1997-05-02 | ||
US08/850,327 US5972372A (en) | 1996-07-31 | 1997-05-02 | Intravaginal rings with insertable drug-containing core |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998004220A1 true WO1998004220A1 (en) | 1998-02-05 |
WO1998004220A9 WO1998004220A9 (en) | 1998-05-28 |
Family
ID=26697614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/012777 WO1998004220A1 (en) | 1996-07-31 | 1997-07-22 | Intravaginal rings with insertable drug-containing core |
Country Status (13)
Country | Link |
---|---|
US (2) | US5972372A (en) |
EP (1) | EP0862396B1 (en) |
JP (1) | JP3970936B2 (en) |
CN (1) | CN1154455C (en) |
AT (1) | ATE290836T1 (en) |
AU (1) | AU4043197A (en) |
BR (1) | BR9706802A (en) |
CA (1) | CA2232635C (en) |
DE (1) | DE69732760T2 (en) |
DK (1) | DK0862396T3 (en) |
ES (1) | ES2239363T3 (en) |
PT (1) | PT862396E (en) |
WO (1) | WO1998004220A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003507109A (en) * | 1999-08-26 | 2003-02-25 | エンハンス ファーマシューティカルズ,インコーポレイティド | Apparatus and method for anesthetizing a female cervix |
JP2003527404A (en) * | 2000-03-21 | 2003-09-16 | エンハンス ファーマシューティカルズ,インコーポレイティド | Devices and methods for treating urinary incontinence in women |
WO2009003125A1 (en) * | 2007-06-26 | 2008-12-31 | Warner Chilcott Company,Inc. | Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
WO2009066006A1 (en) * | 2007-11-22 | 2009-05-28 | Bayer Schering Pharma Oy | Vaginal delivery system |
US7829112B2 (en) | 2003-04-29 | 2010-11-09 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
WO2012170578A1 (en) | 2011-06-06 | 2012-12-13 | Oak Crest Institute Of Science | Drug delivery device employing wicking release window |
EP2585011A2 (en) * | 2010-06-22 | 2013-05-01 | Anu Mahashabde | Intravaginal devices comprising anticholinergic agents, and methods of making thereof |
EP2585010A2 (en) * | 2010-06-22 | 2013-05-01 | Anu Mahashabde | Methods of treating conditions associated with overactive bladder |
WO2014122563A1 (en) * | 2013-02-08 | 2014-08-14 | Qpharma Ab | An intra vaginal device, and a method of reducing the rate of diffusion of active ingredients in said intra vaginal device |
US8865200B2 (en) | 2004-07-09 | 2014-10-21 | Laboratoire Hra Pharma | Sustained release compositions containing progesterone receptor modulators |
WO2015036952A1 (en) | 2013-09-12 | 2015-03-19 | Qpharma Ab | A drug delivery system for one or more active ingredients |
WO2018202574A1 (en) | 2017-05-04 | 2018-11-08 | Bayer Oy | Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception |
WO2020257544A1 (en) * | 2019-06-21 | 2020-12-24 | The Population Council, Inc. | System for providing birth control |
WO2021108722A1 (en) * | 2019-11-27 | 2021-06-03 | Oak Crest Institute Of Science | Sustained release drug delivery device |
US11529308B2 (en) | 2019-06-21 | 2022-12-20 | The Population Council, Inc. | System for providing birth control |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537566B1 (en) | 1999-03-11 | 2003-03-25 | John Alton Copland | Compositions and methods for the non-invasive treatment of uterine fibroid cells |
JP2005503389A (en) * | 2001-08-31 | 2005-02-03 | シエーリング オサケユイチア | Drug delivery system |
WO2003080019A1 (en) * | 2002-03-27 | 2003-10-02 | Galen (Chemicals) Limited | Intravaginal reservoir drug delivery devices |
US8367098B2 (en) * | 2002-04-30 | 2013-02-05 | The Population Council, Inc. | Unique combinations of antimicrobial compositions |
WO2003093322A2 (en) * | 2002-04-30 | 2003-11-13 | The Population Council, Inc. | Carrageenan based antimicrobial compositions |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
TWI336627B (en) | 2003-05-23 | 2011-02-01 | Organon Nv | Drug delivery system,and use and manufacturing method thereof |
US20070043332A1 (en) * | 2003-07-10 | 2007-02-22 | Galen (Chemiclas) Liimited | Intravaginal drug delivery devices |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
US20060185678A1 (en) * | 2005-02-03 | 2006-08-24 | Bronnenkant Lance J | Devices for delivering agents to a vaginal tract |
ATE495752T1 (en) | 2005-07-19 | 2011-02-15 | Population Council Inc | METHOD AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS |
US20100003297A1 (en) * | 2005-08-11 | 2010-01-07 | Massachusetts Institute Of Technology | Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues |
DK1933810T3 (en) | 2005-08-11 | 2013-01-28 | Childrens Medical Center | Intravesical drug delivery device and method |
US20070077269A1 (en) * | 2005-10-04 | 2007-04-05 | Woodward John R | Method of birth control and hormone regulation |
BRPI0709344A2 (en) * | 2006-03-20 | 2011-07-12 | Duramed Pharmaceuticals Inc | flexibly compressed intravaginal ring, its use and preparation process, method of providing an active agent, therapeutic kit and product |
US8399012B2 (en) * | 2006-04-17 | 2013-03-19 | Kimberly-Clark Worldwide, Inc. | Degradable therapeutic delivery device |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
EP2037938A2 (en) * | 2006-07-12 | 2009-03-25 | Controlled Therapeutics (Scotland) Ltd. | Drug delivery polymer with hydrochloride salt of clindamycin |
WO2008021309A1 (en) * | 2006-08-15 | 2008-02-21 | Wyeth | Imidazolidin-2-one derivatives useful as pr modulators |
US7649007B2 (en) * | 2006-08-15 | 2010-01-19 | Wyeth Llc | Oxazolidine derivatives as PR modulators |
US7618989B2 (en) * | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
US7538107B2 (en) | 2006-08-15 | 2009-05-26 | Wyeth | Oxazinan-2-one derivatives useful as PR modulators |
TW200815428A (en) * | 2006-08-15 | 2008-04-01 | Wyeth Corp | Oxazolidone derivatives as PR modulators |
US20080045560A1 (en) * | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
KR20090110355A (en) * | 2007-01-19 | 2009-10-21 | 더 유니버시티 오브 유타 리서치 파운데이션 | Biodegradable intravaginal devices for delivery of therapeutics |
AR066166A1 (en) * | 2007-09-21 | 2009-07-29 | Organon Nv | DRUG SUPPLY SYSTEM |
PL2062569T3 (en) * | 2007-11-22 | 2011-10-31 | Bayer Oy | Vaginal delivery system |
JP5560200B2 (en) * | 2007-12-11 | 2014-07-23 | マサチューセッツ インスチテュート オブ テクノロジー | Implantable drug delivery device for treating bladder and other body vesicles or lumens |
CA3016642A1 (en) * | 2008-02-04 | 2009-08-13 | Ferring B.V. | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
US20100040671A1 (en) * | 2008-08-12 | 2010-02-18 | Ahmed Salah U | Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof |
US8419793B2 (en) * | 2008-09-19 | 2013-04-16 | Mentor Worldwide Llc | Coating with antimicrobial agents |
US8420153B2 (en) * | 2008-09-19 | 2013-04-16 | Mentor Worldwide Llc | Coating with antimicrobial agents |
US20120070476A1 (en) * | 2009-05-29 | 2012-03-22 | Moench Thomas R | Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces |
ES2921527T3 (en) | 2009-06-03 | 2022-08-29 | Forsight Vision5 Inc | Anterior segment drug delivery |
AU2010265866B2 (en) | 2009-06-26 | 2012-07-12 | Taris Biomedical Llc | Solid drug tablets for implantable drug delivery devices |
MX2012000948A (en) * | 2009-07-21 | 2012-02-28 | Population Council Inc | Multi-layered gradient vaginal ring. |
US9017312B2 (en) * | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
US20130096092A1 (en) | 2010-06-10 | 2013-04-18 | Health And Human Services | Thioether prodrug compositions as anti-hiv and anti-retroviral agents |
CA2808276A1 (en) | 2010-08-20 | 2012-02-23 | Teva Women's Health, Inc. | Intravaginal devices, methods of making, and uses thereof |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
MX339735B (en) | 2010-11-12 | 2016-06-07 | The Univ Of Utah Res Found | Intravaginal devices for controlled delivery of lubricants. |
AU2012205654B2 (en) | 2011-01-10 | 2016-09-08 | Allergan, Inc. | Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding |
US9107816B2 (en) * | 2011-02-04 | 2015-08-18 | Taris Biomedical Llc | Implantable device for controlled dissolution and diffusion of low solubility drug |
EP2749286B1 (en) | 2011-08-26 | 2017-03-01 | Universidad De Santiago De Chile | Use of non-steroidal anti-inflammatory drugs meloxicam and piroxicam, administered intravaginally, for interruption of a woman's ovulation process |
RU2740680C2 (en) | 2011-09-14 | 2021-01-19 | Форсайт Вижн5, Инк. | Eye inserter device and methods |
HUE055562T2 (en) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
TW201332585A (en) | 2012-02-14 | 2013-08-16 | Chemo Res S L | Core sheath drug delivery devices |
EP2641602A1 (en) | 2012-03-23 | 2013-09-25 | PregLem S.A. | Method for treating gynecological diseases |
DE102012009057A1 (en) * | 2012-05-09 | 2013-11-14 | Dr. Arabin GmbH & Co. KG | Rotational pessary made from a polymer comprises an active substance against premature births |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
TR201808748T4 (en) | 2012-09-03 | 2018-07-23 | Ecosea Farming S A | Reservoir-cage immersion system for culture and / or conservation of hydrobiological species. |
PT2911623T (en) | 2012-10-26 | 2019-11-21 | Forsight Vision5 Inc | Ophthalmic system for sustained release of drug to eye |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
AU2014215459A1 (en) | 2013-02-05 | 2015-09-17 | The Population Council, Inc. | Intravaginal ring for the delivery of unique combinations of antimicrobial compositions |
ES2949133T3 (en) * | 2013-03-08 | 2023-09-25 | Li Galli B V I O | Vaginal diagnosis and/or drug administration system |
NZ711546A (en) | 2013-03-15 | 2017-12-22 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
CA2907674A1 (en) | 2013-04-10 | 2014-10-16 | Preglem Sa | Progesteron receptor modulators for use in the therapy of uterine fibroids |
ES2956840T3 (en) | 2013-08-19 | 2023-12-29 | Taris Biomedical Llc | Multi-Unit Drug Delivery Devices |
WO2015035003A1 (en) | 2013-09-05 | 2015-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thioether prodrug compositions as anti-hiv and anti-retroviral agents |
WO2015055789A1 (en) | 2013-10-17 | 2015-04-23 | Bayer Pharma Aktiengesellschaft | INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
US10413504B2 (en) | 2013-12-11 | 2019-09-17 | Merck Sharp & Dohme Corp. | Intravaginal ring drug delivery system |
US10596103B2 (en) | 2013-12-11 | 2020-03-24 | Merek Sharp & Dohme B.V. | Drug delivery system for delivery of anti-virals |
RU2697051C2 (en) | 2014-01-28 | 2019-08-09 | Дзе Попьюлэйшн Каунсил, Инк. | Combined medicinal preparation for prevention of sexually transmitted infections |
CA2944436C (en) * | 2014-04-01 | 2023-08-22 | Poly-Med, Inc. | Contraceptive and related device |
US20150306230A1 (en) * | 2014-04-28 | 2015-10-29 | Celanese Acetate Llc | Drug delivery vehicles comprising cellulose derivatives, starch derivatives, and combinations thereof |
EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
BR112014030232A2 (en) * | 2014-06-28 | 2017-06-27 | Laboratorios Andromaco S A | pessary cerclage containing long, sustained and sustained release progesterone useful for preventing premature birth |
EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
EP3285850A1 (en) | 2015-04-23 | 2018-02-28 | TARIS Biomedical LLC | Drug delivery devices with drug-permeable component and methods |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
BR112018070199A2 (en) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | pharmaceutical composition of steroid hormone |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2019084469A1 (en) | 2017-10-27 | 2019-05-02 | Renovia Inc. | Devices, systems, and methods for training pelvic floor muscles |
US10632066B1 (en) | 2019-02-01 | 2020-04-28 | The Population Council, Inc. | Method of providing birth control |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
USD935018S1 (en) * | 2020-04-07 | 2021-11-02 | The Population Council, Inc. | Contraceptive |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4155991A (en) * | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
US4888074A (en) * | 1987-07-22 | 1989-12-19 | Dow Corning France S.A. | Therapeutic rings |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3545439A (en) * | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
BE792502A (en) * | 1971-12-09 | 1973-06-08 | Upjohn Co | NEW PHARMACEUTICAL FORMS AND THEIR PREPARATION PROCESS |
US3920805A (en) * | 1971-12-09 | 1975-11-18 | Upjohn Co | Pharmaceutical devices and method |
IL48277A (en) * | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
US3995633A (en) * | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal Medicament dispensing device |
US3995634A (en) * | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal cavity dispensing means and method |
US3991760A (en) * | 1975-12-02 | 1976-11-16 | The Procter & Gamble Company | Vaginal medicament dispensing means |
JPS5339064U (en) * | 1976-09-08 | 1978-04-05 | ||
US4286587A (en) * | 1978-10-11 | 1981-09-01 | Alza Corporation | Vaginal drug delivery system made from polymer |
US4292965A (en) * | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
US4250611A (en) * | 1979-04-19 | 1981-02-17 | Alza Corporation | Process for making drug delivery device with reservoir |
DE3040978A1 (en) * | 1980-10-28 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | VAGINAL RING |
US4596576A (en) * | 1984-10-12 | 1986-06-24 | Akzo N.V. | Release system for two or more active substances |
ZA857643B (en) * | 1984-10-12 | 1986-05-28 | Akzo Nv | Release system for two or more active substances |
FI95768C (en) * | 1993-06-17 | 1996-03-25 | Leiras Oy | Intravaginal dosing system |
-
1997
- 1997-05-02 US US08/850,327 patent/US5972372A/en not_active Expired - Lifetime
- 1997-07-22 AU AU40431/97A patent/AU4043197A/en not_active Abandoned
- 1997-07-22 DK DK97938007T patent/DK0862396T3/en active
- 1997-07-22 JP JP50891598A patent/JP3970936B2/en not_active Expired - Lifetime
- 1997-07-22 CA CA002232635A patent/CA2232635C/en not_active Expired - Lifetime
- 1997-07-22 WO PCT/US1997/012777 patent/WO1998004220A1/en active IP Right Grant
- 1997-07-22 AT AT97938007T patent/ATE290836T1/en active
- 1997-07-22 EP EP97938007A patent/EP0862396B1/en not_active Expired - Lifetime
- 1997-07-22 PT PT97938007T patent/PT862396E/en unknown
- 1997-07-22 CN CNB971909911A patent/CN1154455C/en not_active Expired - Lifetime
- 1997-07-22 DE DE69732760T patent/DE69732760T2/en not_active Expired - Lifetime
- 1997-07-22 BR BR9706802-0A patent/BR9706802A/en not_active IP Right Cessation
- 1997-07-22 ES ES97938007T patent/ES2239363T3/en not_active Expired - Lifetime
-
1999
- 1999-05-21 US US09/316,640 patent/US6126958A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4155991A (en) * | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
US4888074A (en) * | 1987-07-22 | 1989-12-19 | Dow Corning France S.A. | Therapeutic rings |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003507109A (en) * | 1999-08-26 | 2003-02-25 | エンハンス ファーマシューティカルズ,インコーポレイティド | Apparatus and method for anesthetizing a female cervix |
JP2003527404A (en) * | 2000-03-21 | 2003-09-16 | エンハンス ファーマシューティカルズ,インコーポレイティド | Devices and methods for treating urinary incontinence in women |
JP2013107895A (en) * | 2000-03-21 | 2013-06-06 | Teva Women's Health Inc | Device and method for treating urinary incontinence in female |
US7829112B2 (en) | 2003-04-29 | 2010-11-09 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
US7833545B2 (en) | 2003-04-29 | 2010-11-16 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
US7838024B2 (en) | 2003-04-29 | 2010-11-23 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
US7883718B2 (en) | 2003-04-29 | 2011-02-08 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
US8865200B2 (en) | 2004-07-09 | 2014-10-21 | Laboratoire Hra Pharma | Sustained release compositions containing progesterone receptor modulators |
US8962010B2 (en) | 2007-06-26 | 2015-02-24 | Warner Chilcott Company, Llc | Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
EP3470055A1 (en) * | 2007-06-26 | 2019-04-17 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
WO2009003125A1 (en) * | 2007-06-26 | 2008-12-31 | Warner Chilcott Company,Inc. | Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
WO2009066006A1 (en) * | 2007-11-22 | 2009-05-28 | Bayer Schering Pharma Oy | Vaginal delivery system |
EA018112B1 (en) * | 2007-11-22 | 2013-05-30 | Байер Ой | Vaginal delivery system |
EP2585011A4 (en) * | 2010-06-22 | 2014-10-15 | Teva Womens Health Inc | Intravaginal devices comprising anticholinergic agents, and methods of making thereof |
EP2585010A2 (en) * | 2010-06-22 | 2013-05-01 | Anu Mahashabde | Methods of treating conditions associated with overactive bladder |
EP2585010A4 (en) * | 2010-06-22 | 2014-10-01 | Teva Womens Health Inc | Methods of treating conditions associated with overactive bladder |
EP2585011A2 (en) * | 2010-06-22 | 2013-05-01 | Anu Mahashabde | Intravaginal devices comprising anticholinergic agents, and methods of making thereof |
US9937335B2 (en) | 2011-06-06 | 2018-04-10 | Oak Crest Institute Of Science | Drug delivery device employing wicking release window |
EP2717813A4 (en) * | 2011-06-06 | 2014-11-05 | Oak Crest Inst Of Science | Drug delivery device employing wicking release window |
EP2717813A1 (en) * | 2011-06-06 | 2014-04-16 | Oak Crest Institute of Science | Drug delivery device employing wicking release window |
WO2012170578A1 (en) | 2011-06-06 | 2012-12-13 | Oak Crest Institute Of Science | Drug delivery device employing wicking release window |
US9775905B2 (en) | 2013-02-08 | 2017-10-03 | Qpharma Ab | Intrauterine device and method for reducing the rate of diffusion of active ingredients in said device by adding inert particulates to a polymeric coating |
WO2014122563A1 (en) * | 2013-02-08 | 2014-08-14 | Qpharma Ab | An intra vaginal device, and a method of reducing the rate of diffusion of active ingredients in said intra vaginal device |
US11872284B2 (en) | 2013-02-08 | 2024-01-16 | Qpharma Ab | Intrauterine device, and a method of reducing the rate of diffusion of active ingredients in said intrauterine device |
WO2015036952A1 (en) | 2013-09-12 | 2015-03-19 | Qpharma Ab | A drug delivery system for one or more active ingredients |
WO2018202574A1 (en) | 2017-05-04 | 2018-11-08 | Bayer Oy | Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception |
WO2020257544A1 (en) * | 2019-06-21 | 2020-12-24 | The Population Council, Inc. | System for providing birth control |
US10918649B2 (en) | 2019-06-21 | 2021-02-16 | The Population Council, Inc. | System for providing birth control |
US10925882B2 (en) | 2019-06-21 | 2021-02-23 | The Population Council, Inc. | System for providing birth control |
US10940157B2 (en) | 2019-06-21 | 2021-03-09 | The Population Council, Inc. | System for providing birth control |
US11529308B2 (en) | 2019-06-21 | 2022-12-20 | The Population Council, Inc. | System for providing birth control |
US11850251B2 (en) | 2019-06-21 | 2023-12-26 | The Population Council, Inc. | System for providing birth control |
WO2021108722A1 (en) * | 2019-11-27 | 2021-06-03 | Oak Crest Institute Of Science | Sustained release drug delivery device |
Also Published As
Publication number | Publication date |
---|---|
ATE290836T1 (en) | 2005-04-15 |
EP0862396B1 (en) | 2005-03-16 |
JPH11512965A (en) | 1999-11-09 |
CN1198091A (en) | 1998-11-04 |
CA2232635A1 (en) | 1998-02-05 |
DK0862396T3 (en) | 2005-07-11 |
CN1154455C (en) | 2004-06-23 |
CA2232635C (en) | 2002-09-17 |
DE69732760T2 (en) | 2006-04-13 |
EP0862396A1 (en) | 1998-09-09 |
ES2239363T3 (en) | 2005-09-16 |
US5972372A (en) | 1999-10-26 |
MX9802349A (en) | 1998-08-30 |
PT862396E (en) | 2005-07-29 |
US6126958A (en) | 2000-10-03 |
DE69732760D1 (en) | 2005-04-21 |
JP3970936B2 (en) | 2007-09-05 |
EP0862396A4 (en) | 2000-09-06 |
AU4043197A (en) | 1998-02-20 |
BR9706802A (en) | 1999-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5972372A (en) | Intravaginal rings with insertable drug-containing core | |
WO1998004220A9 (en) | Intravaginal rings with insertable drug-containing core | |
US6103256A (en) | Intravaginal drug delivery device | |
US10532025B2 (en) | Intrauterine delivery system for contraception | |
US4012496A (en) | Vaginal ring | |
US4155991A (en) | Vaginal ring | |
US6416780B1 (en) | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors | |
US4292965A (en) | Intravaginal ring | |
US20080199511A1 (en) | Sustained Release Compositions Containing Progesterone Receptor Modulators | |
EP0970704B1 (en) | Silicone core long term androgen delivery implant | |
EP1256280B1 (en) | Process for making a range of long shelf life, filled bread snacks | |
JPS62298532A (en) | Vagina insert device | |
EP1629844B2 (en) | A longterm delivery system with controlled initial burst | |
WO2010133757A1 (en) | Vaginal delivery system | |
HU176165B (en) | Pessary | |
WO2003080019A1 (en) | Intravaginal reservoir drug delivery devices | |
MXPA98002349A (en) | Intravaginal rings with insertable drug-containing core | |
US20170312219A1 (en) | Method of contraception | |
MXPA99006219A (en) | Silicone core long term androgen delivery implant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97190991.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997938007 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2232635 Country of ref document: CA Ref document number: 2232635 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/002349 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1998 508915 Country of ref document: JP Kind code of ref document: A |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/13-13/13, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997938007 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997938007 Country of ref document: EP |